A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once‐Weekly DPP‐4 Inhibitor, Does Not Prolong the QTc Interval

By  

Clinical Pharmacology In Drug Development, Vol. 5, Iss. 5, 2016-09 ,pp. : 383-392

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiac Safety of Rupatadine in a Single‐Ascending‐Dose and Multiple‐Ascending‐Dose Study in Healthy Japanese Subjects, Using Intensive Electrocardiogram Assessments—Comparison With the Previous White Caucasian Thorough QT Study

By  

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 1, 2018-01 ,pp. : 67-76

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Single Ascending Dose Study of Epigallocatechin Gallate in Healthy Volunteers

By Ullmann U   Haller J   Decourt JP   Girault N   Girault J   Richard-Caudron AS   Pineau B   Weber P  

The Journal of International Medical Research, Vol. 31, Iss. 2, 2003-03 ,pp. : 88-101

Field House Publishing

Access to resources Recommend Favorite

Sample Size Calculation for Thorough QT/QTc Study Considering Various Factors Related to Multiple Time Points

By Meng Zhaoling   Kringle Robert   Chen Xun   Zhao Peng-Liang  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 3, 2010-05 ,pp. : 580-594

Taylor & Francis Ltd

Access to resources Recommend Favorite

Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending‐dose study

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 6, 2015-11 ,pp. : 434-441

John Wiley & Sons Inc

Access to resources Recommend Favorite